In prostate cancer, niclosamide inhibition of migration is proposed to occur through inhibition of the STAT3-AR axis35 and in basal breast cancer the effects of niclosamide is proposed to occur through inhibition of the WNT/β-catenin and STAT3 signalling49. Here, AR is linked to prostate carcinoma.